doi:10.3969/j.issn.1673-8640.2024.02.016

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 14

[1]	GAO X, JIA Y, XU H, et al. Association between serum pepsinogen and atherosclerotic cardiovascular disease[J]. Nutr Metab Cardiovasc Dis, 2021, 31(1):169-177. DOI PMID
[2]	TONG Y, WANG H, ZHAO Y, et al. Serum pepsinogen levels in different regions of China and its influencing factors:a multicenter cross-sectional study[J]. BMC Gastroenterol, 2021, 21(1):264. DOI
[3]	WANG Y, ZHU Z, LIU Z, et al. Diagnostic value of serum pepsinogen Ⅰ,pepsinogen Ⅱ,and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3): 300060520914826.
[4]	KIM D B, JO I H, PAIK C N, et al. Serum pepsinogen and gastrin levels:reliable markers to predict small intestinal bacterial overgrowth[J]. Turk J Gastroenterol, 2022, 33(3):213-220. DOI URL
[5]	ZHAO B, ZHANG M, LIU D, et al. Establishment of reference interval for the tumour marker serum CYFRA 21-1 in healthy Chinese Han ethnic adults[J]. Scand J Clin Lab Invest, 2018, 78(3):171-174. DOI PMID
[6]	XU P, ZHOU Q, XU J. Reference interval transference of common clinical biomarkers[J]. Scand J Clin Lab Invest, 2021, 81(4):264-271. DOI URL
[7]	吴群, 沈隽霏, 吴文浩, 等. 间接法建立总胆红素和直接胆红素参考区间的探讨[J]. 检验医学, 2020, 35(8):749-752. DOI
[8]	Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory[S]. EP28-A3c,CLSI, 2010.
[9]	QI Z, ZHANG L, CHEN Y, et al. Biological variations of seven tumor markers[J]. Clin Chim Acta, 2015, 450:233-236. DOI PMID
[10]	CHIANG T H, CHEN Y N, CHEN Y R, et al. Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori:a community-based study[J]. BMC Gastroenterol, 2022, 22(1):69. DOI
[11]	GRAD C, POP A, GABOREAN E, et al. Value of GastroPanel in the diagnosis of atrophic gastritis[J]. Exp Ther Med, 2021, 22(5):1347. DOI PMID
[12]	金鑫, 李树锦, 陈贞, 等. 血清胃蛋白酶原对幽门螺杆菌感染的诊断价值[J]. 检验医学, 2020, 35(8):791-794. DOI
[13]	唐伟, 李琳, 赵全能, 等. 南充地区汉族健康人群血清胃蛋白酶原和胃泌素-17参考区间调查研究[J]. 检验医学与临床, 2021, 18(10):1361-1364.
[14]	汪杨, 李溪, 梁志伟, 等. 广州地区健康人群胃蛋白酶原参考范围的建立[J]. 检验医学与临床, 2020, 17(4):433-435.

性别	例数	PG I/(μg·L^-1)	PG Ⅱ/(μg·L^-1)	PGR
男性	4 261	46.60(37.80~57.40)	7.20(5.65~9.20)	6.49(5.52~7.52)
女性	2 181	39.80(32.80~48.80)	6.10(4.90~8.30)	6.33(5.30~7.36)
Z值		-18.43	-12.80	-4.65
P值		<0.001	<0.001	<0.001

性别	例数	PG I/(μg·L^-1)	PG Ⅱ/(μg·L^-1)	PGR
男性	4 261	46.60(37.80~57.40)	7.20(5.65~9.20)	6.49(5.52~7.52)
女性	2 181	39.80(32.80~48.80)	6.10(4.90~8.30)	6.33(5.30~7.36)
Z值		-18.43	-12.80	-4.65
P值		<0.001	<0.001	<0.001

组别	例数	PGⅠ/(μg·L^-1)	PGⅡ/(μg·L^-1)	PGR
≤30岁组	1 051	42.90(35.40~51.20)	6.40(5.20~8.10)	6.61(5.63~7.59)
31~40岁组	1 452	44.90(37.13~54.40)^*	6.80(5.50~8.70)^*	6.59(5.62~7.58)
41~50岁组	1 055	49.00(39.80~60.10)^#	7.72(6.10~9.80)^#	6.34(5.34~7.40)^#
51~60岁组	553	52.70(43.45~63.90)^△	8.30(6.60~10.60)^△	6.32(5.37~7.42)
≥61岁组	150	57.50(47.05~70.88)^▲	9.00(7.40~11.60)^▲	6.47(5.37~7.47)
H值		259.65	295.08	24.63
P值		<0.01	<0.01	<0.01

组别	例数	PGⅠ/(μg·L^-1)	PGⅡ/(μg·L^-1)	PGR
≤30岁组	1 051	42.90(35.40~51.20)	6.40(5.20~8.10)	6.61(5.63~7.59)
31~40岁组	1 452	44.90(37.13~54.40)^*	6.80(5.50~8.70)^*	6.59(5.62~7.58)
41~50岁组	1 055	49.00(39.80~60.10)^#	7.72(6.10~9.80)^#	6.34(5.34~7.40)^#
51~60岁组	553	52.70(43.45~63.90)^△	8.30(6.60~10.60)^△	6.32(5.37~7.42)
≥61岁组	150	57.50(47.05~70.88)^▲	9.00(7.40~11.60)^▲	6.47(5.37~7.47)
H值		259.65	295.08	24.63
P值		<0.01	<0.01	<0.01

组别	例数	PGⅠ/(μg·L^-1)	PGⅡ/(μg·L^-1)	PGR
≤30岁组	607	36.80(30.90~44.00)	5.40(4.60~6.90)	6.58(5.67~7.63)
31~40岁组	780	38.90(32.83~46.80)^*	5.90(4.90~7.80)^*	6.35(5.32~7.42)^*
41~50岁组	455	42.00(33.90~51.00)^#	6.60(5.30~9.30)^#	6.27(5.14~7.18)
51~60岁组	221	44.40(36.09~54.80)^△	7.50(5.80~10.75)^△	5.77(4.94~6.79)^△
≥61岁组	118	50.30(40.38~62.58)^▲	8.60(7.08~11.53)^▲	5.81(4.78~6.90)
H值		139.49	206.57	56.74
P值		<0.01	<0.01	<0.01

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 14

Related Articles 15

Recommended Articles

Metrics

项目	PGⅠ/(μg·L^-1)	PGⅡ/(μg·L^-1)	PGR
男性
≤30岁	24.59~75.64	≤12.54	≥4.32
31~40岁	25.23~79.80	≤12.84
41~50岁	26.82~82.52	≤14.00	≥4.01
51~60岁	26.74~88.23	≤14.33
≥61岁	25.23~90.21	≤15.20
女性
≤30岁	21.50~71.40	≤12.00	≥4.35
31~40岁	21.42~69.09	≤12.80	≥3.86
41~50岁	24.80~75.80	≤13.82
51~60岁	23.91~82.98	≤14.90	≥3.53
≥61岁	24.18~77.83	≤15.03

项目	PGⅠ		PGⅡ
项目	本研究参考区间/ (μg·L^-1)	本研究参考区间下限与厂商声明参考区间^①的相对偏差/%	本研究参考区间/(μg·L^-1)	与厂商声明参考区间^①的相对偏差/%
男性
≤30岁	24.59~75.64	184.67	≤12.54	83.41
31~40岁	25.23~79.80	177.45	≤12.84	79.13
41~50岁	26.82~82.52	161.00	≤14.00	64.29
51~60岁	26.74~88.23	161.78	≤14.33	60.50
≥61岁	25.23~90.21	177.45	≤15.20	51.32
女性
≤30岁	21.50~71.40	225.58	≤12.00	91.67
31~40岁	21.42~69.09	226.80	≤12.80	79.69
41~50岁	24.80~75.80	182.26	≤13.82	66.43
51~60岁	23.91~82.98	192.76	≤14.90	54.36
≥61岁	24.18~77.83	189.50	≤15.03	53.03

[1]	YAN Songhe, LI Haiting, BAI Ying, WANG Jing. Influence of Tripterygium wilfordii lactone alcohol regulating Notch4 protein on CAL27 cell activity [J]. Laboratory Medicine, 2024, 39(2): 192-197.
[2]	. [J]. Laboratory Medicine, 2024, 39(2): 189-191.
[3]	. [J]. Laboratory Medicine, 2024, 39(2): 181-184.
[4]	LU Wenyuan, XU Jingya, DING Ning. Diagnostic roles of MPV and DD in the severity of acute cerebral infarction at different infarct sites [J]. Laboratory Medicine, 2024, 39(2): 171-175.
[5]	ZHOU Yingqin, XIAO Yuan, MENG Jun. Roles of fecal calprotectin and other inflammatory indicators in children with Crohn's disease [J]. Laboratory Medicine, 2024, 39(2): 161-165.
[6]	WU Linjun, ZHOU Yi, PU Wenjie, LIU Yusong. Correlation between T lymphocyte subgroup，liver function indexes and TCM syndrome differentiation in chronic hepatitis B patients [J]. Laboratory Medicine, 2024, 39(2): 166-170.
[7]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[8]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[9]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[10]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[11]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[12]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[13]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[14]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[15]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.